Ryzneuta Vitalis Therapeutics

RYZNEUTA (efbemalenograstim alfa) is proposed for use in adults receiving cytotoxic chemotherapy for cancer (treatments that kill cancer cells). It is intended to shorten the time patients have low neutrophil levels (neutropenia), and to prevent febrile neutropenia (neutropenia with fever). It is not proposed for use in chronic myeloid leukaemia or myelodysplastic syndromes (types of blood cancers).